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Abstract
Background: We have previously reported that the sigma-2 receptor is highly expressed in
pancreas cancer. Furthermore, we have demonstrated that sigma-2 receptor specific ligands induce
apoptosis in a dose-dependent fashion. Here, we examined whether sigma-2 receptor ligands
potentiate conventional chemotherapies such as gemcitabine and paclitaxel.
Methods: Mouse (Panc-02) and human (CFPAC-1, Panc-1, AsPC-1) pancreas cancer cell lines
were used in this study. Apoptosis was determined by FACS or immunohistochemical analysis after
TUNEL and Caspase-3 staining. Combination therapy with the sigma-2 ligand SV119 and the
conventional chemotherapies gemcitabine and paclitaxel was evaluated in an allogenic animal model
of pancreas cancer.
Results: SV119, gemcitabine, and paclitaxel induced apoptosis in a dose-dependent fashion in all
pancreas cancer cell lines tested. Combinations demonstrated increases in apoptosis. Mice were
treated with SV119 (1 mg/day) which was administered in combination with paclitaxel (300 μg/day)
over 7 days to mice with established tumors. A survival benefit was observed with combination
therapy (p = 0.0002). Every other day treatment of SV119 (1 mg/day) in combination with weekly
treatment of gemcitabine (1.5 mg/week) for 2 weeks also showed a survival benefit (p = 0.046).
Animals tolerated the combination therapy and no gross toxicity was noted in serum biochemistry
data or on necropsy.
Conclusion: SV119 augments tumoricidal activity of paclitaxel and gemcitabine without major side
effects. These results highlight the potential utility of the sigma-2 ligand as an adjuvant treatment in
pancreas cancer.
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Pancreas cancer is the fourth leading cause of cancer-
related mortality in the United States [1]. The 5-year sur-
vival rate is less than 5% [2]. This poor outcome stems
from the difficulty in achieving an early diagnosis and the
failure of surgery, radiation and chemotherapy. In fact,
only 15% of patients are eligible for surgical resection at
the time of diagnosis [3]. Even after radical pancreatec-
tomy, most patients with pancreas cancer show local
recurrence or metastasis within 1 year. The current stand-
ard chemotherapeutic, gemcitabine, demonstrates a slight
improvement in survival, but these modest results are not
satisfactory [4]. Novel therapeutic strategies are desper-
ately needed.
Standard therapies for pancreatic cancer have two major
limitations. First, systemic administration of chemother-
apy does not selectively target the cancer and is limited by
systemic toxicity. Second, local therapies such as radiation
or surgery do not address the potential for distant metas-
tases. For these reasons, a targeted strategy which directly
delivers the cytotoxic molecule to the cancer is highly
desirable.
There is considerable interest in stimulating apoptosis and
inhibiting survival machinery as components of cancer
therapy [4-6]. Many oncogenic transformations result
from the inactivation or deletion of pro-apoptotic genes
or the translocation of an anti-apoptotic gene down-
stream of highly active promoters [5,7,8]. The sigma-2
receptor is a unique targeting receptor that induces tumor
apoptosis for pancreas cancer. The sigma receptor was ini-
tially proposed as a subtype of opioid receptors [9]. Early
receptor binding studies using benzomorphan opioids
indicated at least two subtypes of sigma receptors exist:
sigma-1 and sigma-2 subtype [5]. These subtypes display
different tissue distributions and distinct physiological
and pharmacological profiles in both the central and
peripheral nervous systems. Although natural ligands for
these receptors are still unknown, recent research has
demonstrated that sigma receptors are over-expressed in a
variety of human and rodent tumors [5,6,10,11] and that
synthetic ligands to this receptor could play an important
role in cancer diagnosis and therapy [12]. We have previ-
ously reported that the sigma-2 receptor is highly
expressed in pancreas cancer and weakly expressed in nor-
mal pancreas [13]. In this same study, we carefully charac-
terized the receptor-ligand binding interaction and
reported the Kd and Bmax values of sigma-2 receptor lig-
ands in models of pancreatic adenocarcinoma. Further-
more, we have demonstrated that sigma-2 receptor
specific ligands induce apoptosis in a dose-dependent
fashion and that this activity occurs, at least in part, via the
intrinsic apoptotic pathway. Because sigma-2 receptor-
specific ligands selectively induce apoptosis in pancreas
cancer, these ligands may act as sensitizers to standard
chemotherapies.
Since pancreatic cancer has proven to be resistant to mod-
ern, conventional therapies, we have chosen to focus our
efforts and developing novel therapeutics that specifically
target this cancer. In this study, we follow up on our pre-
vious characterization of sigma-2 receptor ligands by
demonstrating that these novel agents augment conven-
tional therapies for pancreas cancer and are an exciting




Sigma-2 specific ligands SV119, SV95, and fluorescent -
labeled sigma-2 ligand, SW120, were synthesized and pre-
pared as previously described [13-15]. The Sigma-1 recep-
tor ligand, (+)-pentazocine (Sigma Chemical, St. Louis,
MO), was used as a control.
Cell lines
Murine pancreatic adenocarcinoma, Panc-02, was
obtained from Bryan Clary (Duke University) and main-
tained in supplemented RPMI 1640 containing glutamine
(2 mmol/L), pyruvate (1 mmol/L), penicillin (100 IU/
mL), streptomycin (100 IU/mL), and 10% FBS. Human
pancreatic adenocarcinoma cell lines (Panc-1, AsPC-1,
and CFPAC-1) were obtained from ATCC (Bethesda, MD)
and maintained in Dulbecco's modified eagle's medium
(DMEM) containing glutamine (2 mmol/L), pyruvate (1
mmol/L), penicillin (100 IU/mL), streptomycin (100 IU/
mL), and 10% FBS. HPDE (Human Pancreas Duct Epithe-
lium) was obtained from Dr. Ming Sound Tsao and cul-
tured in Keratinocyte serum-free (KSF) medium (Gibco/
Invitrogen, Carlsbad, CA) with 50 mg/ml bovine pituitary
extract (BPE), 5 ng/ml epidermal growth factor (EGF),
and 1× antibiotic-antimycotic cocktail (Gibco/Invitro-
gen). All cell culture processes were carried out in a
humidified atmosphere of 5% CO2 at 37°C. All cultures
were free of Mycoplasma as assayed by the Washington
University Division of Comparative Medicine. Cultures
were maintained for no longer than 12 weeks after recov-
ery from frozen stocks.
Sigma-2 ligand binding in vitro
Tumor cells were incubated with 10 nM of SW120 (a flu-
orescent-labeled sigma-2 receptor ligand) for 30 minutes.
HPDE cells were used as a normal control. To demon-
strate the specificity of SW120 for Sigma-2 receptor bind-
ing, 10μM of SV95 (Sigma-2 ligand) or (+)-pentazocine
(sigma-1 receptor ligand) were added to cells 30 minutes
prior to SW120 treatment. All lines were then washed 3
times with PBS and evaluated by flow cytometry.Page 2 of 8
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Tumor cells were harvested and seeded at a density of
approximately 0.2 × 106 cells per well in 12-well plates in
1.0 ml culture medium. Seeded cells were split and pre-
incubated for more than 24 hours (Panc-02) and 48 hours
(CFPAC-1, AsPC-1, and Panc-1) to maintain their growth
conditions. SV119 and SW120 were dissolved in DMSO,
and gemcitabine and paclitaxel were dissolved in PBS. The
solutions were then added to the culture medium at the
concentrations indicated with final concentration of
DMSO at less than 1%. The extent of apoptosis was subse-
quently measured as previously described [13]. Briefly,
staining was performed on trypsin-EDTA treated cultures
fixed with 1% paraformaldehyde and 90% methanol.
Fixed cells were resuspended in TUNEL reagent or cleaved
caspase-3 antibody and incubated overnight at room tem-
perature (TUNEL) or 4°C (Caspase 3). After incubated
cells were washed, cells were resuspended in fluorescent
antibody or 7-AAD buffer and incubated for 1 hour at
room temperature. Cell-associated fluorescence was deter-
mined by the flow cytometry (FACScan, BD Biosciences)
and analyzed with CellQuest software (BD Biosciences).
In vivo assessment of apoptosis
Female C57BL/6 mice (8–12 weeks old) were purchased
from the NCI and acclimated for at least 1 week before
tumor implantation. All mice were injected in the right
flank with 200 μl single cell suspension containing 1.0 ×
106 Panc-02 cells. Two weeks after tumor implantation, at
which point the mean tumor diameter was approximately
5 mm, mice were treated with a single intraperitoneal
injection of SV119, conventional chemotherapy, or both.
Twenty-four hours later, tumors were harvested and
minced to 1 mm and digested in a RPMI buffer containing
1 mg/ml collagenase (Sigma-Aldrich, St. Louis, MO) and
0.1 mg/ml DNase (Sigma-Aldrich, St. Louis, MO) for 45
min to obtain a single-cell suspension. After filtering,
erythrocyte contaminants were lysed in Ammonium
Chloride (ACK) buffer, pelleted, and resuspended in PBS
(pH 7.4). Single cell suspensions were fixed by 1% para-
formaldehyde by following the above procedure. Apopto-
sis was then assessed as described above utilizing flow
cytometry.
In vivo assessment of tumor growth and survival
Female C57BL/6 mice (8–12 weeks old) were purchased
from the NCI and acclimated for at least 1 week before
tumor implantation. All mice were injected in the right
flank with 200 μl single cell suspension containing 1.0 ×
106 Panc-02 cells. Treatment of tumors started 2 weeks
after tumor implantation, at which point the mean tumor
diameter was approximately 5 mm. To evaluate the effect
of treatment both systemically and on tumors in vivo, sev-
eral treated mice were sacrificed and blood cytologic
(complete blood count) and biochemical analysis (liver
enzymes, bilirubin, amylase, lipase, BUN, creatinine, glu-
cose) were performed. For the survival study, tumor bear-
ing mice (n = 8–10 per group) were treated with SV119
and/or chemotherapy once daily for 7 days (paclitaxel
treatment model) or every other day for 14 days (gemcit-
abine treatment model). Mean tumor diameter was meas-
ured three times each week. All mice were euthanized
when their tumor ulcerated, reached a mean diameter of
15 mm, or 50 days after initiation of the study. All studies
were performed in accordance with an animal protocol
approved by the Washington University Institutional Ani-
mal Care Facility.
Statistical analysis
Error bars, unless stated otherwise, represent means plus
or minus SEM of an experiment with at least three biolog-
ical replicates. For statistical analysis of differences
between groups, one-way ANOVA was performed. For in
vivo experiments, Kaplan-Meier survival curves were plot-
ted and differences were compared with a log-rank test. A
p-value less than 0.05 was considered significant for all
analysis.
Results
Sigma-2 ligands have a high affinity for pancreatic 
adenocarcinoma cell lines compared to normal cell lines
We have previously reported that murine (Panc-02) and
human (AsPC-1, CFPAC-1, and Panc-1) pancreatic aden-
ocarcinoma cell lines display increased expression of the
sigma-2 receptor [13]. However, we have not previously
compared the binding of Sigma-2 ligands to the normal
human pancreas cell line HPDE. As demonstrated in Fig-
ure 1, Panel A, there is a high affinity of Sigma-2 ligand to
the human pancreatic adenocarcinoma cell line AsPC-1
compared to the immortalized normal pancreatic cell line
HPDE. This binding also appeared to be specific to the
Sigma-2 receptor as we were able to demonstrate compet-
itive inhibition by pretreating with a second Sigma-2 lig-
and, but not a Sigma-1 receptor ligand (pentazocine,
Panel B)
The apoptotic effect of the sigma-2 ligand, SV119, is 
enhanced by conventional chemotherapy in vitro
In order to evaluate the potential therapeutic effect of the
sigma-2 ligand, SV119, in combination with conventional
chemotherapy, we treated pancreatic cancer cell lines with
SV119 and the chemotherapeutic agents gemcitabine and
paclitaxel. After 24 hours of treatment in the presence of
SV119 and gemcitabine or paclitaxel, all cell lines demon-
strated an additive increase in apoptosis as demonstrated
by increases in TUNEL staining (Figure 2). Similar
responses were noted in all cell lines when cleaved caspase
3 was utilized as the endpoint (data not shown).Page 3 of 8
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both G0 and G1 to G2/S phase of pancreatic cancer cells 
in vitro
Next, in order to further characterize this effect, we evalu-
ated the growth phase of these pancreatic cancer cells
under these conditions by co-staining for cleaved caspase-
3 and the proliferation maker Ki-67. As seen in Figure 3,
SV119 and gemcitabine or paclitaxel induced apoptosis in
cells that were both in G0 as well as in G1 to G2/S phase
of the cell cycle. Mean TUNEL-positivity ranged from
16.1% to 18.6% at 10 μM SV119 (Figure 3). Combining
SV119 with a chemotherapy increased apoptosis. Mean
TUNEL-positivity ranged from 26.5% to 70.5% in the
SV119 and gemcitabine combination (50 nM) and from
26.6% to 53.8% in the SV119 and paclitaxel combination
(50 nM). As shown in the representative FACS histogram,
SV119 (10 μM) induced moderate apoptosis in Ki67 neg-
ative cells (G0 phase). Gemcitabine treatment shifted the
cell proliferation from G0 to the active stage with moder-
ate apoptosis (Figure 3). Paclitaxel demonstrated limited
apoptosis in both G0 and active phases of the cancer cell
cycle. These data suggest that SV119 may serve as a sensi-
tizer to these conventional therapies.
The pro-apoptotic activity of the sigma-2 ligand, SV119, is 
enhanced by conventional chemotherapy in vivo without 
cytologic or chemical evidence of systemic toxicity
In order to determine if the pro-apoptotic effect of these
agents was also conferred to tumors in vivo, an implanta-
ble murine tumor model was utilized. In this study, pan-
creatic tumors were implanted into the flank of C57BL/6
mice. Fourteen days after tumor implantation, a single
intraperitoneal treatment on SV119, or SV119 combined
with conventional chemotherapy (gemcitabine or paclit-
axel) was administered. Twenty-four hours later, single
cell suspensions of these tumors were generated and
apoptosis was measured by FACS analysis. As shown in
Sigma-2 ligands have a high affinity for pancreatic adenocarci-no  ce l li e  comp red to normal cell linesFigure 1
Sigma-2 ligands have a high affinity for pancreatic 
adenocarcinoma cell lines compared to normal cell 
lines. Representative FACS analysis of human (A.) and 
murine (B.) pancreatic adenocarcinoma cell lines treated with 
the FITC-conjugated Sigma-2 ligand, SW120. In Panel A, 
HPDE (immortalized pancreatic ductal epithelial cells) were 
used as a control. In Panel B, competitive inhibition of 
SW120 binding was demonstrated by preincubation with the 
Sigma-2 ligand, SW95. Pentazocine, a Sigma-1 receptor lig-
and, was also used as a control and did not demonstrate 
competitive inhibition. Experiments were performed in tripli-
cate with comparable results.
The apoptotic effect of the sigma-2 ligand, SV119, is enhanced by onventional che otherapy in vitroFigure 2
The apoptotic effect of the sigma-2 ligand, SV119, is 
enhanced by conventional chemotherapy in vitro. 
Model pancreatic adenocarcinoma cell lines were treated 
with escalating doses of SV119, SV119 and gemcitabine, or 
SV119 and paclitaxel. After 24 hours of treatment, percent 
caspase-3 positive cells were determined by flow cytometry. 
Results are expressed as the mean, with bars representing 
standard error of the mean. Experiments were performed in 
triplicate with comparable results. Where indicated, * = P < 
0.01 for SV119+gemcitabine or SV119+paclitaxel vs. SV119-
only control.Page 4 of 8
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that were treated with both sigma-2 ligand (SV119) and
conventional chemotherapy (gemcitabine or paclitaxel).
These mice appeared healthy and cytologic/biochemical
laboratory analysis did not reveal major toxicity (Addi-
tional file 1) [16]. Necropsy was also performed on
selected animals and no gross or histologic evidence of
organ dysfunction was observed (data not shown).
Treatment of mice bearing pancreatic tumor allografts 
with the sigma-2 receptor ligand, SV119, and conventional 
chemotherapy slows tumor growth and confers a survival 
advantage
Two different treatment models of SV119 in combination
with conventional chemotherapies were utilized. In the
first model, weekly treatment of gemcitabine (1.5 mg/
week) in combination with every other day treatment of
SV119 was given for 2 weeks (Figure 5). In the second
model, paclitaxel (0.3 mg/day) and SV119 were used as
concurrent daily treatments (Figure 6). A suboptimal dos-
ing regimen was selected to maximize our chances of
detecting a combined effect.
In vivo systemic administration of SV119-alone given as 7
daily doses or as 7 doses every other day for 14 days dem-
onstrated a non significant tumor volume and survival
advantage. Treatment with chemotherapies alone (gem-
citabine or paclitaxel) also demonstrated a limited effect
in both treatment models. However, in both models, the
combination of SV119 with a chemotherapeutic agent sig-
nificantly slowed tumor growth when compared to ther-
apy with single agents or with untreated controls. Animals
tolerated the combination therapy well, without evidence
of cytologic or biochemical toxicity (data not shown).
Discussion
Pancreas cancer remains a devastating malignancy and
novel therapeutic strategies are desperately needed. Can-
cers by definition create and develop in a stressful envi-
ronment (overcrowding, hypoxia, nutrient starvation)
which should promote apoptosis. Therefore most cancers
including pancreas cancer develop numerous strategies
which promote survival and overcome natural signals to
undergo apoptosis [17]. In fact, many experts suggest that
suppression of apoptosis is central to the evolution of can-
cer. It is also an important factor for resistance to many
standard cancer treatments [12,18-21]. Standard therapies
including most chemotherapeutics and radiation therapy
induce cellular stress and thereby promote apoptosis.
Standard therapies capitalize on the premise that cells in
stressful microenvironments have increasing susceptibil-
ity to apoptogenic stimuli when subjected to additional
cellular stressors such as cytotoxic therapeutics. This argu-
ment appears to be true for the common therapeutics uti-
lized in the treatment of pancreas cancer. For example
gemcitabine inhibits DNA replication, indirectly promot-
ing apoptosis, and paclitaxel arrests the cell cycle, directly
promoting apoptosis.
The sigma-2 ligand SV119 induces moderate apoptosis in both G0 and G1 to G2/S phase of pancreatic cancer cells in vitroFigure 3
The sigma-2 ligand SV119 induces moderate apoptosis in both G0 and G1 to G2/S phase of pancreatic cancer 
cells in vitro. The murine pancreatic adenocarcinoma cell, Panc02, was treated with SV119 alone or in combination with gem-
citabine or paclitaxel. After 24 hours of treatment, samples were stained for cleaved caspase-3 and Ki67. Representative histo-
grams are shown from an experiment performed in triplicate.Page 5 of 8
(page number not for citation purposes)
Journal of Translational Medicine 2009, 7:24 http://www.translational-medicine.com/content/7/1/24The sigma-2 receptor and its undiscovered endogenous
ligand(s) is poorly understood. Literature regarding the
role of the sigma-2 receptor in normal homeostasis is
unquestionably lacking. Most of what is understood
about this receptor comes from investigations in tumors.
Several groups of investigators have shown that sigma-2
receptor expression is markedly increased across diverse
malignancies. Recent data have suggested that this upreg-
ulation is related to cell proliferation [5]. This feature has
generated interest in utilizing sigma-2 ligands as radi-
otracers for cancer imaging. Our group has shown that
once the receptor is engaged certain ligands are rapidly
internalized and distributed to membrane-encapsulated
organelles [11]. This finding is consistent with the report
by Ostenfeld et al that siramesine, a sigma-2 receptor
selective ligand, is lysosomotrophic [15].
We and others have recently shown that selected sigma-2
ligands are capable of inducing apoptosis in a multitude
of human and murine cancer cells lines and in animal
models of cancer including pancreas cancer [12,13,15].
The mechanisms by which this works are poorly under-
stood but we do know that the apoptosis generated by
selected sigma-2 ligands can be partially inhibited with
intrinsic pathway inhibitors like caspase inhibitor [13].
While the anti-tumor effects of sigma-2 ligands alone are
modest, the high receptor abundance on cancers and the
high affinity of the ligands for the receptor may present a
unique opportunity to utilize these ligands as chemother-
apeutic sensitizers.
We hypothesized that sigma-2 ligands may selectively
augment the effects of non-selective pro-apoptotic anti-
The pro-apoptotic activity of the sigma-2 ligand, SV119, is enhanced by c nventional chemotherapy in vivoFigure 4
The pro-apoptotic activity of the sigma-2 ligand, 
SV119, is enhanced by conventional chemotherapy in 
vivo. C57BL/6 mice bearing implanted tumor allografts were 
treated with a single dose of SV119 and conventional chemo-
therapy (gemcitabine or paclitaxel). Twenty-four hours after 
treatment, tumors were harvested and single cell suspen-
sions were generated. Percent active caspase-3 was then 
measured in tumor cells by flow cytometry. Each experimen-
tal group represents an n = 3. Results are expressed as the 
mean, with bars representing standard error of the mean.
The sigma-2 ligand, SV119, combined with gemcitabine sup-pres es tumor growth and increas s survival in model pan-c atic aden c rcinom  in vivoFigure 5
The sigma-2 ligand, SV119, combined with gemcitab-
ine suppresses tumor growth and increases survival 
in model pancreatic adenocarcinoma in vivo. C57BL/6 
mice bearing established tumor allografts were treated with 
every other day SV119 (1 mg/mouse, i.p. for 7 days) and 
weekly gemcitabine (3 mg/mouse, i.p. for two weeks). Mean 
tumor diameter (Panel A) and survival (Panel B) were meas-
ured. * = vs. control.Page 6 of 8
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tumor receptor abundance may provide a novel strategy
for improving on the effects of cytotoxic chemotherapies
without increasing toxicity. Since sigma-2 ligands are
expressed on other tissues (although at lower levels) we
were concerned that such a combined strategy might
result in toxicity wherever sigma-2 ligands are found. We
tested whether SV119 (an apoptogenic sigma-2 ligand)
and a standard chemotherapeutic would slow tumor
growth, reduce toxicity, and ultimately improve survival
in a murine model of established pancreas adenocarci-
noma.
In our present study, both the specific ligand of the Sigma-
2 receptor (SV119) and the chemotherapies showed mod-
erate apoptosis in all pancreas cancer cells in vitro. SV119
induced tumor apoptosis in both cycling cells at all phases
(G1 to G2M/S) and in quiescent, G0, cells (Figure 3).
Depending on the cell line assayed, SV119 in combina-
tion with the lower dose of chemotherapies showed an
additive or super-additive effect in inducing tumor apop-
tosis (Figure 3). These results indicate that SV119 is a use-
ful sensitizer for pancreas cancer treatment in
combination with cell cycle specific chemotherapies. In
addition, the combination of SV119 with standard chem-
otherapy may decrease the chemotherapy dose required.
This is significant because it is typically the systemic toxic-
ity of contemporary chemotherapeutics that limit their
effectiveness.
In the allograft C57/BL6 model of pancreas cancer, SV119
treatment in combination with gemcitabine or paclitaxel
led to tumor stability and regression in some cases when
compared to single therapies. Although all tumors
resumed growing shortly after treatment was stopped,
tumors in mice receiving combination treatment grew
more slowly than tumors in either of the single agent
treatments or vehicle-injected control. This result suggests
that combination therapy was not only successful in
reducing tumor mass but also altered the course of tumor
growth after therapy was stopped. Importantly no signifi-
cant toxicities were appreciated by serum biochemistry or
by necropsy and immunohistochemistry.
Conclusion
Pancreas cancer is an aggressive and rapidly metastasizing
tumor and we believe that it is unlikely that a single ther-
apeutic will result in a cure for this devastating cancer.
Here, we have demonstrated that the sigma-2 receptor-
specific ligand, SV-119, potentiates cell death when com-
bined with conventional chemotherapies without appre-
ciable toxicity in model pancreatic adenocarcinoma. It is
highly critical to investigate novel strategies which might
complement or enhance other proven anti-cancer regi-
mens for the treatment of pancreas cancer. We believe that
this experimental design highlights a new potential strat-
egy for the treatment of pancreas cancer and warrants fur-
ther exploration.
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Additional file 1
Table S1 – Serum toxicology and cytology of mice treated with the 
sigma-2 ligand, SV119, and conventional chemotherapy. Peripheral 
blood was drawn from tumor-bearing mice 24 hours after treatment with 
a single dose of SV119 and conventional chemotherapy (gemcitabine or 
paclitaxel). Cytologic and serum chemistry evaluations were performed by 
the animal care facility at Washington University. Data is expressed as 
mean +/- standard error of the mean. Each experimental group represents 
an n = 2.
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